AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer

• Status: Recruiting
• Trial end date: 2029-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single arm multicenter non-randomized phase II trial testing the efficacy of the combination of carboplatin plus atezolizumab in metastatic ILC

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Netherlands Cancer Institute
• Collaborator: Roche Pharma AG
• Treatments: Antibodies, Monoclonal; Atezolizumab; Carboplatin

Criteria

Inclusion Criteria:

• Signed and written informed consent

• Age 18 year or older

• Metastatic or incurable locally advanced lobular breast cancer with confirmation of the lobular histology and E-cadherin loss on a biopsy of a metastatic lesion.

• Metastatic lesion accessible for histological biopsies

• Evidence of progression of disease

• A maximum of two lines of palliative chemotherapy

• WHO performance status of 0 or 1

• Evaluable disease or measurable according to RECIST 1.1

Exclusion Criteria:

• Leptomeningeal disease localization

• History of having received other anticancer therapies within 2 weeks of start of the study drug

• History of immunodeficiency, autoimmune disease, conditions requiring immunosuppression

• Prior treatment with immune checkpoint blockade

• Live vaccine within 2 weeks prior to start of study

• Active other cancer

• Active hepatitis B